Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
Targeting Inflammation in IBD: Localized vs Systemic Strategies
David T. Rubin, MD
Michael Dolinger, MD, MBA
Putting It All Together: Challenges Addressed
Ugonna Iroku, MD, MHS
Beyond Biology: Environmental and Lifestyle Influences in IBD
Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP
Florence Odufalu, MD
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
June 15, 2026 Chicago, Illinois
Clear Skin, Clear Path: Transforming Psoriasis Care with Durable Biologic and Oral IL-23 Innovations
June 12, 2026 Denver, Colorado
Retina Rumble: Debating Modern Treatment Options
Roger A. Goldberg, MD, MBA
Christina Y. Weng, MD, MBA, FASRS
Yasha S. Modi, MD
Incorporating Novel Muscarinic Agents for Schizophrenia Into Clinical Practice: Overcoming Clinical Inertia
May 28, 2026 Miami Beach, Florida
The Future of HNSCC: Aligning Teams, Transforming Care
Ravindra Uppaluri, MD, PhD
Nancy Lee, MD, FASTRO
IBD Masterclass: Foundations of Pathophysiology and Targeted Therapy
Pathophysiology of IBD: The War Within
Understanding the Microbiome’s Role in IBD Management
The 2-Point Signal: Apply ≥2-Point Rule
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Shared Goals, Shared Gains: Align With Patient Preferences
The IgG Clock: Redose Using IgG Kinetics
IBD Beyond Symptoms: What Community GIs Need to Know
Genetic Susceptibility in IBD: From Risk Genes to Clinical Impact
FcRn: Same Class, Different Paths—Spot Agent Differentiators
Turning Flares Into Function: Flag Uncontrolled Disease
Target Locked in gMG: Why T2T Matters
When to Begin FcRn: Initiation Criteria, Key Evidence
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
Enriqueta Felip, MD
Kristi Orbaugh, MSN, RNP, AOCN
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026 Orlando, Florida
Escalate With Intention: Stepwise, Target-Anchored Moves
Shifting the Script: Personalizing Overactive Bladder Treatment in Complex Patients
David Staskin, MD
Matt T. Rosenberg, MD
Kennedy Koebbe, MSN, RN
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
Hong Zhang
Mechanism-Based Targeting: Why APRIL Matters in IgAN
Suzuki Yusuke, MD, PhD
Dana Rizk, MD
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.